Tenaya Therapeutics, Inc. Earnings Per Share, Basic and Diluted
Tenaya Therapeutics, Inc. (TNYA) reported Earnings Per Share, Basic and Diluted of -$0.69 per share for the 3-month period ending 2022-06-30, per its 10-Q filed 2022-08-10.
Discontinued › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasicAndDiluted · last filed 2022-08-10
- Tenaya Therapeutics, Inc. earnings per share, basic and diluted for the quarter ending 2022-06-30 was -$0.69.
- Tenaya Therapeutics, Inc. earnings per share, basic and diluted for the quarter ending 2022-03-31 was -$0.75.
- Tenaya Therapeutics, Inc. earnings per share, basic and diluted for the quarter ending 2021-12-31 was -$0.63.
- Tenaya Therapeutics, Inc. earnings per share, basic and diluted for the quarter ending 2021-09-30 was -$0.68.
- Tenaya Therapeutics, Inc. earnings per share, basic and diluted for fiscal 2021 was -$4.10.
- Tenaya Therapeutics, Inc. earnings per share, basic and diluted for fiscal 2020 was -$39.50.
| Period end | Earnings Per Share, Basic and Diluted 3 month | Earnings Per Share, Basic and Diluted 6 month | Earnings Per Share, Basic and Diluted 9 month | Earnings Per Share, Basic and Diluted 12 month |
|---|---|---|---|---|
| 2022-06-30 | -$0.69 10-Q · filed 2022-08-10 | -$1.44 10-Q · filed 2022-08-10 | -$2.07 derived: net income ÷ weighted average shares · filed 2023-11-08 | -$2.75 derived: net income ÷ weighted average shares · filed 2023-11-08 |
| 2022-03-31 | -$0.75 10-Q · filed 2022-05-11 | -$1.38 derived: net income ÷ weighted average shares · filed 2023-11-08 | -$2.06 derived: net income ÷ weighted average shares · filed 2023-11-08 | -$3.27 derived: net income ÷ weighted average shares · filed 2023-11-08 |
| 2021-12-31 | -$0.63 derived: net income ÷ weighted average shares · filed 2023-03-08 | -$1.30 derived: net income ÷ weighted average shares · filed 2023-03-08 | -$2.57 derived: net income ÷ weighted average shares · filed 2023-03-08 | -$4.10 10-K · filed 2022-03-23 |
| 2021-09-30 | -$0.68 10-Q · filed 2021-11-10 | -$2.39 derived: net income ÷ weighted average shares · filed 2022-11-10 | -$4.75 10-Q · filed 2021-11-10 | -$7.54 derived: net income ÷ weighted average shares · filed 2022-11-10 |
| 2021-06-30 | -$13.26 10-Q · filed 2022-08-10 | -$25.21 10-Q · filed 2022-08-10 | -$35.19 derived: net income ÷ weighted average shares · filed 2022-11-10 | -$45.59 derived: net income ÷ weighted average shares · filed 2022-11-10 |
| 2021-03-31 | -$11.93 10-Q · filed 2022-05-11 | -$21.83 derived: net income ÷ weighted average shares · filed 2022-11-10 | -$32.15 derived: net income ÷ weighted average shares · filed 2022-11-10 | -$41.47 derived: net income ÷ weighted average shares · filed 2022-11-10 |
| 2020-12-31 | -$9.85 derived: net income ÷ weighted average shares · filed 2022-03-23 | -$20.14 derived: net income ÷ weighted average shares · filed 2022-03-23 | -$29.39 derived: net income ÷ weighted average shares · filed 2022-03-23 | -$39.50 10-K · filed 2022-03-23 |
| 2020-09-30 | -$10.29 10-Q · filed 2021-11-10 | -$19.53 derived: net income ÷ weighted average shares · filed 2021-11-10 | -$29.65 10-Q · filed 2021-11-10 | |
| 2020-06-30 | -$9.21 10-Q · filed 2021-09-08 | -$19.32 10-Q · filed 2021-09-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |